Literature DB >> 6114326

Hypouricaemic effect of polyethyleneglycol modified urate oxidase.

S Davis, Y K Park, A Abuchowski, F F Davis.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 6114326     DOI： 10.1016/s0140-6736(81)90528-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  New advances in the treatment of gout: review of pegloticase.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Ther Clin Risk Manag       Date:  2010-10-27       Impact factor: 2.423

Review 3.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 4.  Tumor lysis syndrome: pathogenesis and management.

Authors:  D P Jones; H Mahmoud; R W Chesney
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

5.  Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.

Authors:  Chun Zhang; Kai Fan; Xuefeng Ma; Dongzhi Wei
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

Review 6.  Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.

Authors:  A G Fam
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

Review 7.  Uricase and other novel agents for the management of patients with treatment-failure gout.

Authors:  John S Sundy; Michael S Hershfield
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.